Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) LT-Debt-to-Total-Asset: 0.41 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09637 Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
5 GF Score
Price HK$25.00
! 1 Warning Sign
View Full Analysis

What is Alebund Pharmaceuticals (Jiangsu) LT-Debt-to-Total-Asset?

Alebund Pharmaceuticals (Jiangsu) HKSE:09637 -2.87% 5 LT-Debt-to-Total-Asset is 0.41 as of Dec. 2025. GuruFocus rates HKSE:09637 with a GF Score™ of 5/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Alebund Pharmaceuticals (Jiangsu)'s long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.41.

Alebund Pharmaceuticals (Jiangsu)'s long-term debt to total assets ratio increased from . 20 (0.00) to Dec. 2025 (0.41). It may suggest that Alebund Pharmaceuticals (Jiangsu) is progressively becoming more dependent on debt to grow their business.

Alebund Pharmaceuticals (Jiangsu)  (HKSE:09637) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Alebund Pharmaceuticals (Jiangsu) LT-Debt-to-Total-Asset Related Terms

Alebund Pharmaceuticals (Jiangsu) LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Alebund Pharmaceuticals (Jiangsu)'s LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alebund Pharmaceuticals (Jiangsu) LT-Debt-to-Total-Asset Chart

Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend Dec24 Dec25
LT-Debt-to-Total-Asset
0.40 0.41

Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24 Dec25
LT-Debt-to-Total-Asset 0.40 0.41
HKSE:09637
5GF Score
Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alebund Pharmaceuticals (Jiangsu) LT-Debt-to-Total-Asset Calculation

Alebund Pharmaceuticals (Jiangsu)'s Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=602.881/1480.257
=0.41

Alebund Pharmaceuticals (Jiangsu)'s Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=602.881/1480.257
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.41 mean?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a LT-Debt-to-Total-Asset of 0.41 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors.
Is Alebund Pharmaceuticals (Jiangsu)'s LT-Debt-to-Total-Asset too high?
Alebund Pharmaceuticals (Jiangsu)'s current LT-Debt-to-Total-Asset is 0.41. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s LT-Debt-to-Total-Asset compare to LLY and JNJ?
Alebund Pharmaceuticals (Jiangsu)'s LT-Debt-to-Total-Asset of 0.41 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. Alebund Pharmaceuticals (Jiangsu)'s current LT-Debt-to-Total-Asset is 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current LT-Debt-to-Total-Asset of 0.41. The current LT-Debt-to-Total-Asset is 0.41. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current LT-Debt-to-Total-Asset is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alebund Pharmaceuticals (Jiangsu) Business Description

Address No. 7 Jinzhuang Road, Building 7, High-tech Zone, Gaoxin District, Hanjiang District, Jiangsu Province, Yangzhou, CHN
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score

Get the complete analysis for HKSE:09637

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$25.00
Price